Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929161 · ClinicalTrials.gov registry record · Phase 1
Study of Wellness Behaviors as a Function of Oxytocin vs Placebo
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 239
- Enrollment target
NCT01929161: Completed Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
NCT01929161 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 239 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (298% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01929161, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 239 participants
- Enrollment target
Study Summary
The specific aim of this study is to test whether oxytocin (OT) boosts the positive emotion yield of a new wellness behavior (Lovingkindness meditation or Mindfulness meditation) and thereby increases nonconscious motives that shape daily behavioral decisions to repeat it, which in turn foster positive emotions that further augment nonconscious motives in an upward spiral dynamic. The proposed research targets three hypotheses: (1) Oxytocin manipulation magnifies (i.e., moderates) the positive emotion yield of Lovingkindness meditation; (2) The positive emotion yield of meditation, which varies by experimental condition, increases the nonconscious incentive salience of Wellness Behavior-related cues; and (3) Behavioral decisions predict positive emotions, sparking the relationships among OT manipulation, positive emotion yield, and nonconscious incentive salience of Wellness Behavior-related cues.
Primary Outcome
Modified Daily Emotions Scale (mDES) - This measure of explicit positive affect has been successfully used by the PI in multiple studies to detect changes in positive emotion. Previous work by the PI found that Cronbach's alpha coefficient for the mDES positive emotion composite variable was 0.93 in sample of mid-life community adults similar to those anticipated for this study.
Interventions
- DRUG Oxytocin
- BEHAVIORAL Mindfulness Meditation
- DRUG Placebo (for oxytocin)
- BEHAVIORAL Lovingkindness Meditation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT01929161 record still lists
NCT01929161 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (298% higher).
The record links to 0 conditions, and to 4 interventions - of which Oxytocin is the first listed.
NCT01929161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01929161 about?
NCT01929161 is a clinical study titled "Study of Wellness Behaviors as a Function of Oxytocin vs Placebo". The specific aim of this study is to test whether oxytocin (OT) boosts the positive emotion yield of a new wellness behavior (Lovingkindness meditation or Mindfulness meditation) and thereby increases nonconscious motives that shape daily behavioral decisions to repeat it, which in turn foster posit...
What is the current status of trial NCT01929161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 239 participants. The study started on 2013-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01929161?
The interventions under investigation include: Oxytocin (DRUG), Mindfulness Meditation (BEHAVIORAL), Placebo (for oxytocin) (DRUG), Lovingkindness Meditation (BEHAVIORAL).
Who is sponsoring clinical trial NCT01929161?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01929161's enrollment target sits among peer trials
239 212th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia